sanotize
(2)
Mikael Svensson
Mikael Svensson is Chief Executive Officer of SaNOtize Research and Development Corp., the Vancouver-based company commercializing nitric oxide as an antimicrobial platform, most recently through its NOWONDER consumer nasal cleanser. A chemical engineer by training with more than two decades in medical device and pharmaceutical commercialization, he previously led the global launch of INOmax inhaled nitric oxide therapy and worldwide expansion work on Restylane, Naftin, Mederma and VagiVital.
Steven Basta
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.